Author(s): Ludek Pour, Lucie Brozova, Ivan Spicka, et. al. Abstract: S 1290 Session topic: 14. Myeloma and other monoclonal gammopathies – Clinical Background: The combination of pomalidomide and low-dose dexamethasone (Pom-Dex) is a perspective option for patients with end-stage relapsed/refractory multiple myeloma (RRMM). We analyzed efficacy and toxicity of Pom-Dex in all...
Pro zobrazení tohoto obsahu je třeba být přihlášen.